Antithrombotic efficacy of direct oral anticoagulants on patency rate following microsurgical anastomosis in crushed rat arteries

J Orthop Sci. 2019 May;24(3):552-557. doi: 10.1016/j.jos.2018.10.011. Epub 2018 Nov 2.

Abstract

Background: During the last decade direct oral anticoagulants (DOAC) have been established in various fields of medicine.Their use in microsurgery has not been evaluated yet though. This study aims to evaluate their efficacy in microsurgery and additionally compare them with a well established antithrombotic agent.

Materials and methods: The right femoral artery of 101 rats divided into 4 groups, was crushed and anastomosed. Group A (20 rats) received placebo therapy (1 ml NaCl 0.9%, orally), while Group B (27 rats), Group C (27 rats) and Group D (27 rats) received rivaroxaban (3 mg/kg, orally), dabigatran (30 mg/kg, orally) and enoxaparin (30 mg/kg, subcutaneously) respectively. All drugs were administered 3 h preoperatively and once daily for the following postoperative days until the sacrifice of the animals. Patency was evaluated at 1st, 7th and 20th postoperative day. Following patency evaluation the rats were sacrificed and the vessels were harvested for histological examination.

Results: None of the rats died postoperatively. Patency rates of rivaroxaban group (78%), dabigatran group (70%) and enoxaparin group (63%) were statistically similar, but significantly higher than the placebo-treated control group (p < 0.05). Cells with morphologic features of endothelial cells were evident 7 days after the injury.

Conclusion: The results of this study demonstrate the following: (1) rivaroxaban and dabigatran through inhibition of thrombus formation significantly enhanced the patency rate compared to placebo treatment (2) the antithrombotic efficacy of rivaroxaban and dabigatran in compromised microvessels was similar to that of enoxaparin, the most widely used antithrombotic agent.

MeSH terms

  • Anastomosis, Surgical
  • Animals
  • Dabigatran / therapeutic use*
  • Enoxaparin / therapeutic use*
  • Factor Xa Inhibitors / therapeutic use*
  • Femoral Artery / surgery
  • Male
  • Microsurgery*
  • Rats
  • Rats, Wistar
  • Rivaroxaban / therapeutic use*
  • Vascular Patency / drug effects*

Substances

  • Enoxaparin
  • Factor Xa Inhibitors
  • Rivaroxaban
  • Dabigatran